CONTEXT AND OBJECTIVE: Osteoporosis is a skeletal disorder characterized by low bone mineral density (BMD). Studies have shown that some of the genetic components relating to lower BMD may be detected by polymorphisms. Our aim was to evaluate the frequencies of interleukin-6, GST and progesterone receptor gene polymorphisms in postmenopausal women with low BMD. DESIGN AND SETTING: Cross-sectional study, conducted in a public university in São Paulo, Brazil.
INTRODUCTION
Osteoporosis is a skeletal disorder characterized by low bone mineral density (BMD) and deterioration of bone microarchitecture, thus predisposing towards a risk of fractures. It is estimated to affect more than 75 million people worldwide. The risk factors among women include: race, lower height, body mass index, lowcalcium diet, use of corticosteroids for over six months, smoking and menopausal status. 1 Earlier studies showed that environmental effects and genetic control influenced bone turnover. 2, 3 Back in 1991, genetic inheritance was shown to be 45-85% likely to be a determinant of mineral density. 2 Since then, various genes have been investigated. [3] [4] [5] [6] [7] Studies have shown that some of the genetic components relating to lower BMD may be detected by gene polymorphisms such as interleukin-6 (IL-6) polymorphism. [8] [9] [10] [11] IL-6 is a phosphoric acid-containing glycoprotein with 185 amino acids and it is located in chromosome 7p21. It is a multifunctional cytokine produced by mononuclear cells and is regulated by the presence of polymorphisms. In fact, the C-G exchange in nucleotide 174 affects the transcription of this gene by decreasing its expression. IL-6 gene transcriptional activity is also marked in the presence of polymorphism in the promoter region (174 G/C). Presence of the C allele mutant is associated with low IL-6 plasma levels; however, presence of the G wild allele is related to high plasma levels of this cytosine. 12 Some authors have observed increased IL-6 levels in postmenopausal women in response to lower levels of estradiol, 13 and that gene polymorphism influenced bone resorption. Glutathione S-transferases (GSTs) are a family of enzymes that regulate conversion of toxic compounds to hydrophilic metabolites. GSTs are responsible for metabolization and peroxidation of estrogens and lipids, and their polymorphism frequency is related to ethnic factors. 18, 19 There are three main genes involved in these polymorphisms: GSTM1, GSTT1 and GSTP1.
GSTM1 is a gene located in chromosome 1p13.3 and is not expressed by 20% to 50% of individuals. 18 Studies have suggested that genetic alterations such as in GSTM1 may increase the levels of estrogen and/or catechol estrogens, which might be associated with estrogen-dependent diseases.
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OBJECTIVE
The aim of our work was to estimate the frequencies of interleukin-6, GST and progesterone receptor gene (PROGINS)
polymorphisms in postmenopausal women with low BMD.
METHODS
This was a cross-sectional study, conducted in a public university in São Paulo, Brazil, including 110 patients with no sample size calculation prior to the study initiation.
One hundred and ten women in their first ten years after the menopause (mean age of 52 years) were recruited. All patients provided their informed consent to participate in this study and the Local Ethics Committee approved the related protocol. This study was supported by the Department of Gynecology and there was no external sponsor.
The inclusion criteria were that the women needed to have been postmenopausal for 5 to 10 years and needed to present follicle-stimulating hormone, FSH > 35 mUI/ml and estradiol < 20 pg/ml, and that a bone densitometry scan done before hormone therapy needed to be available.
The exclusion criteria comprised absence of bone densitometry before hormone therapy and no use of corticosteroids. None of the subjects had received any medication known to affect bone metabolism (such as glucocorticoids, thyroxin, anti-epileptics, bisphosphonates, calcitonin or hormone replacement therapy for more than three months).
All the subjects underwent careful physical examination and medical history review, including personal data, such as age, race, age at the menopause and medications currently used. Bone mineral density was evaluated using the Lunar DPX-L equipment (Lunar, Madison, Wisconsin, United States), which, according to the criterion of "z-bottom of form, z-top", described by Kiebzak et al., 22 achieves a coefficient of variation of 0.62%. The measurements were performed on the lumbar spine. The T-score and the Z-score were calculated. For comparison with polymorphisms, a T-score cutoff at -1 was used to define low bone mineral density.
Samples of oral scrapings were collected using a cytobrush which was rubbed against the oral mucus lining and then placed The significance level was taken to be 0.05. To estimate the risks of the polymorphisms, a logistic regression model was applied to each polymorphism, using a 95% confidence interval.
RESULTS
In our population, 94% of the women were Caucasian. Regarding IL-6 polymorphism, the composition of the groups was that 64 women were GG (homozygotes) and 48 were GC/CC (only two patients were CC). In relation to PROGINS, there were 87 women with P1/P1 (wild homozygotes) and 23 with positive PROGINS genotypes of the progesterone receptors, P1/P2 (heterozygote). The GSTM1 polymorphism analysis showed that in 30 women, the allele was absent (0/0) and, in 80 women, the allele genotype was present (1/1).
Demographic and clinical variables were compared among homozygotes and heterozygotes for the IL6 genotype. There were significant differences in the L2/L4 T-score (P = 0.03) and BMD (P = 0.05) among the genotype groups ( Table 1) .
To facilitate the odds ratio calculation, the cutoff point for the L2/L4 T-score was adjusted to -1. In this manner, we found that women with polymorphism in one allele, i.e. who were heterozygous for IL-6, presented a risk of having a L2/L4
T-score lower than -1.0 that was 2.3 times higher than those without this polymorphism.
No statistical differences were found between the genotype groups for the PROGINS and GSTM1 polymorphisms regarding clinical variables (Tables 2 and 3 ).
DISCUSSION
In our study, we found that G-C polymorphism in region 174
of the IL-6 gene was associated with low bone mineral density. On the other hand, Garnero et al. 25 found that there were no significant associations between genotypes, bone turnover marker polymorphism and bone turnover or BMD in a cohort of healthy French women. They concluded that IL-6
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polymorphism was weakly associated with the peak BMD level and the rate of postmenopausal forearm trabecular bone loss.
According to those authors, IL-6 genotypes accounted only for a small proportion of the variation of both peak BMD and rate of bone loss.
Even though no specific studies have reported polymorphisms of the PROGINS and GSTM1 genes in relation to BMD, we decided to study these polymorphisms. These occurrences can be explained by progesterone action on bone formation and the influence of GSTM1 on estrogen metabolization.
It has been implied that GSTs are important molecules involved in activation of cytoprotection genes 18 and in correlation with the breast because of their ability to metabolize estrogens and lipids through peroxidation. 20 This may also keep osteoporosis from manifesting, due to hyperestrogenism. This change to this gene could influence bone mass. Some studies have observed that progesterone stimulates proliferation of bone cells. This can be explained by increased insulin growth factor (IGF-2) levels, which could potentially stimulate proliferation of osteoblasts. 15 Growth factor beta, together with insulinoid factor, is the most abundant growth factor in the bone, but the effect of progesterone on growth factor beta in osteoblasts is still unknown. 26, 27 In our study, we also evaluated PROGINS and GST gene polymorphisms regarding age, weight, IMC and BMD variables. We did not find any statistical correlation among them.
We reported that there was a significant association between polymorphisms of the IL-6 gene and BMD. The clinical importance of these findings may lead to new directions for osteoporosis management, such as biomarkers and molecular targets in therapeutics.
However, in fact, there were several limitations to our study. It is possible that the sample size was inadequate for detecting small differences in the groups, and that the study power was suboptimal. Moreover, the lack of a matched control group consisting of women with normal BMD limits the conclusions of this study. It is important to reproduce this study in other populations in order to achieve better analysis and functional outcomes.
CONCLUSION
This study showed that there was a considerable frequency of polymorphisms of the IL-6 gene in women with low BMD.
However, this was not found for the other genes under investigation. Knowledge of osteoporosis-related genetic mechanisms may facilitate prevention and selection of women for therapeutics and prognosis.
